{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:37:38Z","timestamp":1761183458961,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.dmpk.2015.01.001","type":"journal-article","created":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T17:10:06Z","timestamp":1422033006000},"page":"214-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy"],"prefix":"10.1016","volume":"30","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2015.01.001_bib1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1528-1157.1996.tb00650.x","article-title":"Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy","volume":"37","author":"Eriksson","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmpk.2015.01.001_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00007691-199610000-00001","article-title":"Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication","volume":"18","author":"May","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2015.01.001_bib3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00007691-199712000-00003","article-title":"Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy","volume":"19","author":"Battino","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2015.01.001_bib4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","article-title":"Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service","volume":"46","author":"Morris","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.01.001_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","article-title":"Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy","volume":"39","author":"Grasela","year":"1999","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.01.001_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-199904000-00008","article-title":"Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications","volume":"21","author":"Armijo","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2015.01.001_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2000.00237.x","article-title":"Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children","volume":"50","author":"Chen","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.01.001_bib8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00007691-200112000-00006","article-title":"Population pharmacokinetics of lamotrigine","volume":"23","author":"Chan","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2015.01.001_bib9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archneur.62.9.1432","article-title":"Effect of antiepileptic drug comedication on lamotrigine clearance","volume":"62","author":"Weintraub","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.dmpk.2015.01.001_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00228-007-0308-2","article-title":"Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions","volume":"63","author":"Reimers","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.01.001_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","article-title":"Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy","volume":"30","author":"Rivas","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2015.01.001_bib12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1248\/bpb.35.487","article-title":"Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients","volume":"35","author":"Yamamoto","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.dmpk.2015.01.001_bib13","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2710.2012.01351.x","article-title":"Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics","volume":"37","author":"Brzakovi\u0107","year":"2012","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.dmpk.2015.01.001_bib14","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/aps.2012.118","article-title":"Population pharmacokinetics of lamotrigine in Chinese children with epilepsy","volume":"33","author":"He","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.dmpk.2015.01.001_bib15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1528-1167.2006.00423.x","article-title":"Predictors of lamotrigine-associated rash","volume":"47","author":"Hirsch","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmpk.2015.01.001_bib16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jcph.13","article-title":"Do children have the same vulnerability to metabolic drug\u2013drug interactions as adults? A critical analysis of the literature","volume":"53","author":"Salem","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.01.001_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.WNL.0000138424.33979.0C","article-title":"Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy","volume":"63","author":"Hirsch","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.dmpk.2015.01.001_bib18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmpk.2015.01.001_bib19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1528-1167.2007.01274.x","article-title":"Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study)","volume":"49","author":"Tompson","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmpk.2015.01.001_bib20","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1212\/01.wnl.0000277698.33743.8b","article-title":"Lamotrigine extended-release as adjunctive therapy for partial seizures","volume":"16","author":"Naritoku","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.dmpk.2015.01.001_bib21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00228-014-1719-5","article-title":"Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy","volume":"70","author":"Yamamoto","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2015.01.001_bib22","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.107.015214","article-title":"Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4","volume":"35","author":"Miyagi","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2015.01.001_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1067\/mpd.2002.125256","article-title":"Efficacy, tolerability, and kinetics of lamotrigine in infants","volume":"141","author":"Mikati","year":"2002","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.dmpk.2015.01.001_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.dmpk.2015.01.001_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","article-title":"Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy","volume":"57","author":"Gidal","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.dmpk.2015.01.001_bib26","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmpk.2015.01.001_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","article-title":"Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study","volume":"21","author":"May","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2015.01.001_bib28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1528-1157.2000.tb00218.x","article-title":"Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction","volume":"41","author":"Besag","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.dmpk.2015.01.001_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","article-title":"The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy","volume":"95","author":"Gulcebi","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.dmpk.2015.01.001_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/FTD.0b013e3181ceecc6","article-title":"UGT2B7_-161C\u00a0>\u00a0T polymorphism is associated with lamotrigine concentration-to-dose ratio in a multivariate study","volume":"32","author":"Blanca S\u00e1nchez","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.dmpk.2015.01.001_bib31","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","article-title":"Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy","volume":"34","author":"Lovri\u0107","year":"2012","journal-title":"Ther Drug Monit"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436715000026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436715000026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:51:52Z","timestamp":1761162712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715000026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1347436715000026"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2015.01.001","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2015.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}